提高类药物的战略方法作为下一代治疗方法
Panchali Barman1, Shubhi Joshi2, Sheetal Sharma3
1Institute of Forensic Science and Criminology (UIEAST), Panjab University, Sector 14, Chandigarh, 160014 India.
概括
治疗药物正在作为传统药物的替代品获得引力,通过创新的设计和交付策略克服过去的局限性. 本综述探讨了基于计算和修改的方法,用于开发有效的基于的药物.
科学领域:
- 药物发现和开发 药物发现和开发
- 药用化学 医学化学
- 生物技术是生物技术.
背景情况:
- 耐药性疾病需要新的治疗策略.
- 基于的药物提供了一个有希望的替代品,但面临着诸如降解和生物可用性差等挑战.
- 最近在基修饰和设计方面的进步正在使人们对它们的治疗潜力重新产生兴趣.
研究的目的:
- 提供基于的治疗方法的全面概述.
- 突出在体和基于修改的类设计策略.
- 讨论用于提高临床疗效的交付方面的进展.
主要方法:
- 对in-silico (计算) 设计方法的审查.
- 分析用于增强的化学修饰策略.
- 对新型递送系统的检查.
主要成果:
- 确定传统类药物的关键局限性.
- 展示修改策略如何克服这些局限性.
- 目前和新兴的配送技术的概述.
结论:
- 由于改进的设计和交付,类疗法越来越可行.
- 在和化学修改对于开发稳定和有效的来说至关重要.
- 对递送方法的进一步研究将增强临床翻译.
相关概念视频
Structure-Activity Relationships and Drug Design
801
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
801
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Prodrugs
2.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.7K
Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
Principles of Drug Action
6.2K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.2K


